KATIE SWEARINGEN: Open Payments
NPI 1730748344 · MURFREESBORO, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$885 in 34 payments from 14 companies in 2025. Trend: 2023 $0 · 2024 $25 · 2025 $885
Food & beverage: $885
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $161 |
| Galderma Laboratories, L.P. | 2 | $159 |
| Axsome Therapeutics, Inc. | 3 | $124 |
| Otsuka America Pharmaceutical, Inc. | 4 | $99 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $67 |
| PFIZER INC. | 2 | $46 |
| Sumitomo Pharma America, Inc. | 2 | $44 |
| Janssen Pharmaceuticals, Inc | 2 | $43 |
| REVANCE THERAPEUTICS, INC. | 1 | $37 |
| Astellas Pharma US Inc | 1 | $34 |
Products named: Auvelity, REXULTI, VRAYLAR, CAPLYTA, QULIPTA, GEMTESA, SPRAVATO, DAXXIFY.
Industry payments across TN — which companies pay providers there.
